Alpelisib联合氟维司群治疗PIK3CA突变HR+/HER2-晚期乳腺癌:SOLAR-1最终总生存结果
SOLAR-1试验最终总生存分析显示,在PIK3CA突变、HR+/HER2-晚期乳腺癌患者中,Alpelisib联合氟维司群组中位OS为39.3个月,安慰剂联合氟维司群组为31.4个月(HR=0.86,95%CI 0.64-1.15,P=0.15),未跨越预设疗效边界。尽管未达统计学显著性,但数值上延长了7.9个月,且伴肝/肺转移患者HR=0.68,至化疗时间延长(HR=0.72)。
要点
- PIK3CA突变队列中位OS:Alpelisib组39.3个月 vs 安慰剂组31.4个月,HR=0.86,未达统计学显著。
- 伴肝和/或肺转移患者中位OS:37.2个月 vs 22.8个月,HR=0.68(95%CI 0.46-1.00)。
- 至化疗时间:23.3个月 vs 14.8个月,HR=0.72(95%CI 0.54-0.95)。
核心结论
- 在PIK3CA突变、HR+/HER2-晚期乳腺癌中,Alpelisib联合氟维司群虽未跨越预设OS疗效边界,但中位OS数值上延长7.9个月。
- 结果进一步支持该联合方案在此预后不良人群中观察到的显著PFS获益。
研究设计与样本
- SOLAR-1为随机、双盲、安慰剂对照III期试验,入组AI治疗进展的HR+/HER2-晚期乳腺癌男性和绝经后女性。
- 按1:1随机接受Alpelisib(300 mg/日)联合氟维司群(500 mg每28天一次,第15天一次)或安慰剂联合氟维司群。
- PIK3CA突变队列共341例,OS采用Kaplan-Meier法及单侧分层log-rank检验,O'Brien-Fleming疗效边界为P≤0.0161。
主要发现
- PIK3CA突变队列中位OS:Alpelisib联合组39.3个月(95%CI 34.1-44.9),安慰剂联合组31.4个月(95%CI 26.8-41.3),HR=0.86(95%CI 0.64-1.15;P=0.15)。
- 伴肝和/或肺转移患者中位OS:Alpelisib联合组37.2个月(95%CI 28.7-43.6),安慰剂联合组22.8个月(95%CI 19.0-26.8),HR=0.68(95%CI 0.46-1.00)。
- 至化疗中位时间:Alpelisib联合组23.3个月(95%CI 15.2-28.4),安慰剂联合组14.8个月(95%CI 10.5-22.6),HR=0.72(95%CI 0.54-0.95)。
- 更长随访未观察到新的安全性信号。
关键数值与推荐
- OS预设疗效边界为单侧P≤0.0161,实际P=0.15未跨越。
- PIK3CA突变队列样本量n=341。
临床怎么用
- 对于PIK3CA突变、HR+/HER2-晚期乳腺癌经AI进展者,Alpelisib联合氟维司群可考虑作为治疗选择,尤其伴肝/肺转移者可能获益更明显。
- 该方案可延长至化疗时间,延迟化疗启动。
局限性
- OS分析未达到预设统计学显著性边界,数值改善需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancers (ABCs) and is associated with poor prognosis. The SOLAR-1 trial showed that the addition of alpelisib to fulvestrant treatment provided statistically significant and clinically meaningful progression-free survival (PFS) benefit in PIK3CA-mutated, HR+, HER2- ABC. PATIENTS AND METHODS: Men and postmenopausal women with HR+, HER2- ABC whose disease progressed on or after aromatase inhibitor (AI) were randomized 1 : 1 to receive alpelisib (300 mg/day) plus fulvestrant (500 mg every 28 days and once on day 15) or placebo plus fulvestrant. Overall survival (OS) in the PIK3CA-mutant cohort was evaluated by Kaplan-Meier methodology and a one-sided stratified log-rank test was carried out with an O'Brien-Fleming efficacy boundary of P ≤ 0.0161. RESULTS: In the PIK3CA-mutated cohort (n = 341), median OS [95% confidence interval (CI)] was 39.3 months (34.1-44.9) for alpelisib-fulvestrant and 31.4 months (26.8-41.3) for placebo-fulvestrant [hazard ratio (HR) = 0.86 (95% CI, 0.64-1.15; P = 0.15)]. OS results did not cross the prespecified efficacy boundary. Median OS (95% CI) in patients with lung and/or liver metastases was 37.2 months (28.7-43.6) and 22.8 months (19.0-26.8) in the alpelisib-fulvestrant and placebo-fulvestrant arms, respectively [HR = 0.68 (0.46-1.00)]. Median times to chemotherapy (95% CI) for the alpelisib-fulvestrant and placebo-fulvestrant arms were 23.3 months (15.2-28.4) and 14.8 months (10.5-22.6), respectively [HR = 0.72 (0.54-0.95)]. No new safety signals were observed with longer follow-up. CONCLUSIONS: Although the analysis did not cross the prespecified boundary for statistical significance, there was a 7.9-month numeric improvement in median OS when alpelisib was added to fulvestrant treatment of patients with PIK3CA-mutated, HR+, HER2- ABC. Overall, these results further support the statistically significant prolongation of PFS observed with alpelisib plus fulvestrant in this population, which has a poor prognosis due to a PIK3CA mutation. CLINICALTRIALS. GOV ID: NCT02437318.
引用
- André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2020. PMID: 33246021. doi:10.1016/j.annonc.2020.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。